

Professor Simon Benita



Professor Simon Benita is the Former Director and Member of the Institute for Drug Research and the School of Pharmacy, Faculty of Medicine at The Hebrew University of Jerusalem, where he received his Ph.D. in Pharmacy in 1980. His research is focused on polymeric Nano and Microparticulate and lipid-based drug delivery systems aimed at improving ocular bioavailability, dermal penetration and drug targeting. Innovative original nano particulate carriers

for enhanced oral bioavailability of poorly absorbed and highly lipophilic drugs which can be subjected to massive pre-systemic metabolism and P-gp efflux pump effect are currently under investigation.

As a result of his research activities, Prof. S. Benita formed and supervises a group of 38 M.Sc., 27 Ph.D. students, and 18 post-doctoral fellows in pharmaceutical sciences. He has published 156 research articles and 20 book chapters, edited or co-edited 5 books and been issued 35 patents and patent applications.

Professor Benita has served as a member of the Board of Pharmaceutical Sciences of the International Pharmacy Federation and Governor of the Controlled Release Society. He is currently a Foreign Correspondent of Academie Nationale de Pharmacie, France and Governor of The International Microencapsulation Society. He was a member of the Editorial Boards of Pharmaceutical Development and Technology, AAPS PharmSciTech and the European Journal of Pharmaceutics & Biopharmaceutics. He is a member of the Editorial Boards of Journal of Microencapsulation, Journal of Drug Delivery Science and Technology and Annales Pharmaceutiques Francaises.

He was selected to be a recipient of The Hebrew University Kaye Innovation Award in 2000, 2005 and again in 2014, and is an AAPS Fellow.

He is Chevalier dans l'Ordre National du Mérite (Knight in National Order of Merit), France, and granted the Israel Controlled Release Society Chapter Prize for Outstanding Achievements in Controlled Release, in 2012.

He is the Founder of the Novagali Pharma in Ophthalmology acquired by Santen Co. Japan, 2012 and NanoBioSim Ltd (BNS) (2015) focusing on innovative nano-carriers as the solution of choice for enhanced topical drug delivery to improve delivery profile and therapeutic performance.